Callan Family Office LLC Takes $5.77 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Callan Family Office LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 66,996 shares of the medical equipment provider’s stock, valued at approximately $5,768,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZBH. Keating Financial Advisory Services Inc. acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $54,000. Allworth Financial LP acquired a new position in shares of Zimmer Biomet during the second quarter worth approximately $190,000. B. Metzler seel. Sohn & Co. AG acquired a new position in shares of Zimmer Biomet during the second quarter worth approximately $1,926,000. Hara Capital LLC bought a new stake in shares of Zimmer Biomet during the second quarter valued at approximately $176,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Zimmer Biomet during the second quarter valued at approximately $345,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 2.1%

Shares of NYSE ZBH opened at $101.01 on Friday. The company’s 50 day simple moving average is $92.64 and its 200 day simple moving average is $91.00. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The firm has a market capitalization of $19.27 billion, a P/E ratio of 24.58, a P/E/G ratio of 2.69 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ZBH has been the subject of several research analyst reports. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Barclays decreased their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. Zacks Research cut Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Truist Financial boosted their target price on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Finally, UBS Group reaffirmed a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.